GoodRx (GDRX) vs Innodata (INOD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
GoodRx (GDRX) has outperformed Innodata (INOD) over the past year, gaining 7.7% versus a loss of 45.4%. Over five years, INOD leads with a +326.1% price change compared with -92.1% for GDRX. GoodRx is the larger company by market cap ($996.1 million vs $966.8 million), about 1.0 times the size, while Innodata is growing revenue faster (+47.6% vs +0.6%).
On valuation, GoodRx trades at a lower forward P/E (8.3x vs 14.9x for Innodata). Innodata converts more of its revenue into profit, with a net margin of 12.8% versus 3.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GDRX | INOD |
|---|---|---|
| Share price | $2.92 | $28.12 |
| Market cap | $996.14M | $966.84M |
| 1-day change | -3.31% | -8.91% |
| YTD return | +7.75% | -44.81% |
| 1-year return | +7.75% | -45.36% |
| 5-year return | -92.07% | +326.06% |
| P/E ratio (TTM) | 58.40 | 20.38 |
| Forward P/E | 8.29 | 14.91 |
| EPS (TTM) | $0.05 | $1.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $796.85M | $251.66M |
| Revenue growth (YoY) | +0.57% | +47.64% |
| Net income (latest FY) | $30.44M | $32.18M |
| Gross margin | 92.77% | 39.53% |
| Operating margin | 10.98% | 15.84% |
| Net margin | 3.82% | 12.79% |
| 52-week high | $3.89 | $125.14 |
| 52-week low | $1.77 | $27.84 |
| Distance from 52-week high | -24.94% | -77.53% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +35.27% | +296.51% |
| Average volume | 1.09M | 1.56M |
| Shares outstanding | 107.18M | 34.38M |
| Employees | 697 | 10,020 |
| Sector | Technology | Technology |
| Industry | EDP Services | EDP Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GDRX has outperformed INOD by 53.1 percentage points over the past year.
- GoodRx trades at a higher earnings multiple (58.4x vs 20.4x trailing P/E).
- Innodata is more profitable, keeping 12.8 cents of every revenue dollar as net income versus 3.8 cents for GoodRx.
- Innodata grew revenue faster in its latest fiscal year (+47.64% vs +0.57%).
About GoodRx
GDRX stock →GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.
Technology · EDP Services · 697 employees
About Innodata
INOD stock →Innodata Inc. operates as a data engineering company in the United States, the United Kingdom, the Netherlands, Canada, Germany, Belgium, and internationally.
Technology · EDP Services · 10,020 employees
GDRX vs INOD FAQ
Which is bigger, GoodRx or Innodata?
GoodRx (GDRX) is larger, with a market capitalization of $996.14M compared with $966.84M for Innodata (INOD).
Which stock has performed better over the past year, GDRX or INOD?
GDRX returned +7.75% over the past 12 months, compared with -45.36% for INOD (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, GDRX or INOD?
INOD has the lower trailing P/E at 20.4, versus 58.4 for GDRX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are GoodRx and Innodata in the same industry?
Yes. Both are classified in the EDP Services industry within the Technology sector.